Immunological effects of multikinase inhibitors for kidney cancer: A clue for integration with cellular therapies?

Research output: Contribution to journalArticle

Abstract

The multikinase inhibitors Sunitinib and Sorafenib not only inhibit angiogenesis and tumor growth, but also have the potential of interacting with the function of the immune system. Presently available data seem to suggest that Sorafenib may exert immune suppressive effects, whilst the effects of Sunitinib are not so clear, being immune stimulatory in the vast majority - but not all - the studies reported. Trials of combination of these multikinase inhibitors with different types of immune manipulation - and cellular therapies in particular - should be rationally designed taking into account all these complex effects, which ultimately deserve further insights.

Original languageEnglish
Pages (from-to)333-338
Number of pages6
JournalJournal of Cancer
Volume2
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Kidney Neoplasms
Musculoskeletal Manipulations
Immune System
Therapeutics
Growth
Neoplasms
sorafenib
sunitinib

Keywords

  • Cellular therapies
  • Immunology
  • Kidney cancer
  • Multikinase inhibitors

ASJC Scopus subject areas

  • Oncology

Cite this

@article{6aa1b6dd6a914c8889c210e99b5c0954,
title = "Immunological effects of multikinase inhibitors for kidney cancer: A clue for integration with cellular therapies?",
abstract = "The multikinase inhibitors Sunitinib and Sorafenib not only inhibit angiogenesis and tumor growth, but also have the potential of interacting with the function of the immune system. Presently available data seem to suggest that Sorafenib may exert immune suppressive effects, whilst the effects of Sunitinib are not so clear, being immune stimulatory in the vast majority - but not all - the studies reported. Trials of combination of these multikinase inhibitors with different types of immune manipulation - and cellular therapies in particular - should be rationally designed taking into account all these complex effects, which ultimately deserve further insights.",
keywords = "Cellular therapies, Immunology, Kidney cancer, Multikinase inhibitors",
author = "Camillo Porta and Chiara Paglino and Ilaria Imarisio and Carlo Ganini and Paolo Pedrazzoli",
year = "2011",
doi = "10.7150/jca.2.333",
language = "English",
volume = "2",
pages = "333--338",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "1",

}

TY - JOUR

T1 - Immunological effects of multikinase inhibitors for kidney cancer

T2 - A clue for integration with cellular therapies?

AU - Porta, Camillo

AU - Paglino, Chiara

AU - Imarisio, Ilaria

AU - Ganini, Carlo

AU - Pedrazzoli, Paolo

PY - 2011

Y1 - 2011

N2 - The multikinase inhibitors Sunitinib and Sorafenib not only inhibit angiogenesis and tumor growth, but also have the potential of interacting with the function of the immune system. Presently available data seem to suggest that Sorafenib may exert immune suppressive effects, whilst the effects of Sunitinib are not so clear, being immune stimulatory in the vast majority - but not all - the studies reported. Trials of combination of these multikinase inhibitors with different types of immune manipulation - and cellular therapies in particular - should be rationally designed taking into account all these complex effects, which ultimately deserve further insights.

AB - The multikinase inhibitors Sunitinib and Sorafenib not only inhibit angiogenesis and tumor growth, but also have the potential of interacting with the function of the immune system. Presently available data seem to suggest that Sorafenib may exert immune suppressive effects, whilst the effects of Sunitinib are not so clear, being immune stimulatory in the vast majority - but not all - the studies reported. Trials of combination of these multikinase inhibitors with different types of immune manipulation - and cellular therapies in particular - should be rationally designed taking into account all these complex effects, which ultimately deserve further insights.

KW - Cellular therapies

KW - Immunology

KW - Kidney cancer

KW - Multikinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84866874594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866874594&partnerID=8YFLogxK

U2 - 10.7150/jca.2.333

DO - 10.7150/jca.2.333

M3 - Article

AN - SCOPUS:84866874594

VL - 2

SP - 333

EP - 338

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 1

ER -